Y-27632 is associated with corticosteroid-potentiated control of pulmonary remodeling and inflammation in guinea pigs with chronic allergic inflammation by Pigati, Patricia Angeli et al.
  Universidade de São Paulo
 
2015
 
Y-27632 is associated with corticosteroid-
potentiated control of pulmonary remodeling
and inflammation in guinea pigs with chronic
allergic inflammation
 
 
BMC Pulmonary Medicine. 2015 Aug 12;15(1):85
http://dx.doi.org/10.1186/s12890-015-0073-4
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Clínica Médica - FM/MCM Artigos e Materiais de Revistas Científicas - FM/MPT
RESEARCH ARTICLE Open Access
Y-27632 is associated with corticosteroid-
potentiated control of pulmonary
remodeling and inflammation in guinea
pigs with chronic allergic inflammation
Patricia Angeli Pigati1*, Renato Fraga Righetti1, Samantha Souza Possa1, Beatriz Saraiva Romanholo3,4,5,
Adriana Palmeira Dias Rodrigues1, Anelize Sartori Alves dos Santos1, Débora Gonçalves Xisto2,
Mariana Alves Antunes2, Carla Máximo Prado1, Edna Aparecida Leick1, Milton de Arruda Martins1,
Patrícia Rieken Macedo Rocco2 and Iolanda de Fátima Lopes Calvo Tibério1
Abstract
Background: Previously, we showed that treatment with the Rho-kinase inhibitor Y-27632 was able to control
airway responsiveness, inflammation, remodeling, and oxidative stress in an animal model of asthma, suggesting
that this drug is beneficial in asthma. However, studies evaluating the effects of these inhibitors in conjunction with
corticosteroids on chronic pulmonary inflammation have not been conducted. Therefore, we evaluated the effects
of treatment with the Rho-kinase inhibitor Y-27632, with or without concurrent dexamethasone treatment, on
airway and lung tissue mechanical responses, inflammation, extracellular matrix remodeling, and oxidative stress in
guinea pigs with chronic allergic inflammation.
Methods: The guinea pigs were subjected to seven ovalbumin or saline inhalation exposures. Treatment with
Y-27632 (1 mM) and dexamethasone (2 mg/kg) started at the fifth inhalation. Seventy-two hours after the seventh
inhalation, the pulmonary mechanics were evaluated and exhaled nitric oxide (ENO) levels were determined. The
lungs were removed and histological analysis was performed using morphometry.
Results: The treatment of guinea pigs with the Rho-kinase inhibitor and dexamethasone (ORC group) decreased
ENO, the maximal mechanical responses after antigen challenge, inflammation, extracellular matrix remodeling and
oxidative stress in the lungs.
This therapeutic strategy reduced the levels of collagen and IFN-γ in the airway walls, as well as IL-2, IFN-γ,
8-iso-PGF2α and NF-κB in the distal parenchyma, when compared to isolated treatment with corticosteroid or
Rho-kinase inhibitor (P < 0.05) and reduced the number of TIMP-1-positive cells and eosinophils in the alveolar
septa compared to corticosteroid-treated animals (P < 0.05). The combined treatment with the Rho-kinase inhibitor
and the corticosteroid provided maximal control over the remodeling response and inflammation in the airways
and parenchyma.
Conclusions: Rho-kinase inhibition, alone or in combination with corticosteroids, can be considered a future
pharmacological tool for the control of asthma.
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Background
Asthma is a complex chronic respiratory disease that de-
pends on the interaction of genetic and environmental
factors [9], and it features the activation of Th2 cells.
Studies in humans and in animal asthma models have
shown that inflammation, obstruction, and remodeling
occur not only in the proximal airways but also in the dis-
tal pulmonary parenchyma [1, 5, 49]. The impairment of
the distal airways is recognized as an important factor
contributing to airflow obstruction [23], particularly in
patients with severe asthma and nocturnal asthma [7].
The remodeling response in asthmatics contributes to
significant changes in the structures of the proximal and
distal airways [40], as well as in the extent of airflow ob-
struction. This process involves airway smooth muscle
hypertrophy and hyperplasia, mucous gland hyperplasia,
and an increase in the thickness of the airway wall [4].
Currently, anti-inflammatory therapies, such as corticoste-
roids, are considered the gold-standard treatment for
asthma, particularly during an acute asthma attack. Corti-
costeroids inhibit numerous pro-inflammatory responses
and induce numerous anti-inflammatory pathways. How-
ever, the development of new drugs that control this
disease is essential for patients with severe, corticosteroid-
insensitive asthma [18] and to decrease the collateral
systemic effects of steroid use.
Under physiologic conditions, smooth muscle contrac-
tion is controlled by the phosphorylation of the myosin
light chains [35] via Rho-mediated Ca2+ sensitization [45],
or by myosin phosphatase activity, which dephosphory-
lates the myosin light chains [15] independently of the
cytoplasmic calcium concentration [21].
The inhibition of Rho/Rho-kinase pathway may be con-
sidered a potential pharmacological and therapeutic target
in lung diseases [47] because it relaxes the airway smooth
muscle tone and decreases airway inflammation and re-
modeling. These various functions are associated with
changes in the actin cytoskeleton, including cell adhesion,
motility, migration, and contraction [50]. The increased
activity of Rho-kinase in the vascular smooth muscle
under pathophysiological conditions has been reported in
hypertensive animal models [33] and in humans [26].
Thus, inhibitors of Rho/Rho-kinase that relax the airway
smooth muscle and reduce muscle tone are predicted to
be relevant to asthma treatment [6, 12].
Recently, our research group published promising
results using the Rho-kinase inhibitor Y-27632 in an ani-
mal model of chronic allergic inflammation. Treatment
with Y-27632 (a pyridine derivative, (+)-(R)-trans–4-
(1-aminoethyl)-N-(4-pyridyl) cyclohexane carboxamide), a
selective inhibitor of Rho-kinase family enzymes, in sensi-
tized animals reduced lung mechanics, inflammation,
remodeling and oxidative stress in the airway and lung
tissue [36, 41].
Considering the relevance of corticosteroids as the gold
standard treatment for asthma and aiming to complement
our previous research, the focus of the present study was
to evaluate the importance of combining a new class of
drugs for controlling bronchial smooth muscle contrac-
tion with a corticosteroid. Knowing that the peripheral
lung tissue is involved in asthma physiopathology, espe-
cially in severely asthmatic patients [13], we decided to
broaden our research focus to not only include the evalu-
ation of the airways but also study the lung parenchyma.
We believe that this approach differentiates our study
from those previously conducted by comprehensively cov-
ering two different compartments that determine the
pathogenesis of this disease.
Methods
Animals
The animals weighed approximately 300–350 g initially
and were approximately 3 weeks old. All guinea pigs were
humanely cared for during all experimental procedures
and in full compliance with the “Guide for care and use of
laboratory animals” (NIH publication 85–23, revised
1985). All of the experiments described in this study were
supervised and approved by the Institutional Review
Board of the University of São Paulo (São Paulo, Brazil).
The experimental model of pulmonary allergic
inflammation
Chronic airway inflammation was induced as previously
described [1, 24, 25]. The guinea pigs were individually
placed in plexiglass boxes (30 × 15 × 20 cm) coupled to
an ultrasonic nebulizer (Soniclear, São Paulo, Brazil), and
an aerosol of ovalbumin solution (Grade V, Sigma Chem-
ical Co., Saint Louis, MO) diluted in 0.9 % NaCl sterile sa-
line solution was generated for 15 min or until respiratory
distress occurred. This protocol consists of a total of seven
inhalation exposures. The exposures were performed
twice a week for four weeks, with increasing concentra-
tions of ovalbumin (1–5 mg/mL) to avoid tolerance
(Fig. 1). For inhalations 1 to 4 (first two weeks), the dose
of ovalbumin used was 1.0 mg/mL. On the fifth and sixth
inhalations, animals received a solution with 2.5 mg/mL
of ovalbumin, and for the seventh inhalation, the dose was
increased to 5.0 mg/mL. The control animals received
aerosolized saline [51].
Treatment with Rho-kinase inhibitor
From the fifth inhalation of the experimental protocol
onward, the guinea pigs were exposed for 2 min by
inhalation to 1 mM Y-27632 for 10 min before each
ovalbumin or normal saline exposure, as described in a
previous study [17]. The authors of that study verified
that a 2 min inhalation exposure with 1 mM of
Y-27632 inhibited acetylcholine-induced increases in
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lung resistance without altering the mean blood pres-
sure. They performed acetylcholine exposures 10 min
after inhalation of Y-27632 and verified that 1 h later,
the drug was already affecting lung resistance. We did
not give a higher concentration of Y-27632 by intraven-
ous injection because it can decrease the mean blood
pressure, as shown in hypertensive rats [52]. In our
study, on the day of the mechanical evaluation, the
Y-27632 inhalation exposure was performed 1 h before
the start of the experiment. We opted to administer the
drug via inhalation because of the direct effect on the
respiratory system and to minimize systemic effects.
Corticosteroid treatment
To avoid interference with the OVA sensitization, im-
mediately before the fifth inhalation the guinea pigs re-
ceived dexamethasone (2 mg/.kg-1/day i.p.) five hours
before ovalbumin or saline inhalation until the end of
the experimental protocol. In a previous study, using
the passive cutaneous anaphylaxis technique (PCA), we
observed an increase in specific IgG1 homocytotropic
anaphylactic antibodies in guinea pigs that received
four inhalation exposures with ovalbumin at the end of
the second week of the PCA protocol [25, 44].
Experimental groups
Five groups of guinea pigs were studied:
A) animals that received normal saline (SAL, n = 8);
B) animals that received ovalbumin (OVA, n = 8);
C) animals that received ovalbumin and Y-27632
after the fifth inhalation exposure (OVA-RHO
group, n = 8);
D) animals that received ovalbumin and corticosteroids
(OVA-C group, n = 8);
E) animals that received ovalbumin, Y-27632 after the
fifth inhalation, and corticosteroid treatment (ORC
group, n = 8).
The experiment was performed in duplicate to evalu-
ate the oscillatory distal lung mechanics.
Measurement of ENO
Seventy-two hours after the last inhalation exposure, the
guinea pigs were anesthetized with pentobarbital sodium
(50 mg/kg, intraperitoneal injection), a tracheotomy was
performed and the animals were mechanically ventilated
at 60 breaths/min with a tidal volume of 8 mL/kg using a
Harvard 683 ventilator (Harvard Apparatus, USA). After
that, the exhaled nitric oxide (ENO) level was measured as
previously described [25, 37]. Briefly, to obtain the ENO
levels after stabilization of the animal on the ventilator, a
collection bag was attached to the expiratory output of the
ventilator and exhaled air was collected for 3 min. ENO
was measured by a chemiluminescence technique using a
fast-responding analyzer (NOA 280; Sievers Instruments,
Boulder, CO). The analyzer was calibrated with a certified
47 parts per billion (ppb) NO source (White Martins, São
Paulo, Brazil) and zero nitric oxide (NO) filter (Sievers
Instruments) before each measurement. The NO filter
Fig. 1 Timeline of the experimental protocol. The guinea pigs received 7 inhalation exposures (2 per week over 4 weeks) with aerosols of saline
(SAL group) or ovalbumin solution (OVA group) containing an increasing dose of the antigen. From the 1st to the 4th exposures, the animals
received 1 mg/mL ovalbumin (first two weeks). In the 5th and 6th exposures (third week), the animals received 2.5 mg/mL ovalbumin, and in the
7th exposure (beginning of the fourth week), a dose of 5 mg/mL of antigen was used. The solution of ovalbumin or saline was continuously
aerosolized for either 15 min or until respiratory distress occurred. After the 5th exposure, the guinea pigs in the Rho-kinase inhibitor group
received Y-27632 (1 mM; 2 min) by inhalation (OVA-RHO group) and/or dexamethasone (2 mg/kg-1/day i.p.) (OVA-C groups or ORC groups)
10 min before each exposure to OVA or SAL until the end of the experimental protocol. Seventy-two hours following the seventh exposure, the
animals were anesthetized and exsanguinated, the exhaled nitric oxide was collected, and the mechanics of the respiratory system (Ers and Rrs)
and the oscillatory parameters of the distal lung tissue (Et and Rt) were evaluated under basal conditions and after challenge with OVA (0.1 %).
Afterwards, lung slices were removed and submitted to histopathological evaluation
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was attached to the inspiratory input to avoid environ-
mental contamination.
Pulmonary mechanics evaluation
Respiratory system mechanics
After the ENO measurement, mechanical evaluation was
conducted. The tracheal pressure (Ptr) was measured
using a 142PC05D differential pressure transducer
(Honeywell, Freeport, IL) connected to a side tap in the
tracheal cannula. Airflow (V’) was obtained using a
pneumotachograph (Fleish-4-0, Richmond, VA) con-
nected to the tracheal cannula and to a Honeywell
163PC01D36 differential pressure transducer. Lung vol-
ume (V) changes were determined by digital integration
of the airflow signal. Nine to ten respiratory cycles were
averaged to provide one data point. The Ptr, V’ , and V
signals were collected before and after the SAL or OVA
challenge and were stored in a microcomputer [37, 44, 51].
The baseline measurements of Ptr and V’ were per-
formed after stabilization of the animal on the ventilator.
Afterwards, the animals were exposed to 2 min of inhal-
ation of either an aerosol of ovalbumin (30 mg/mL, given
to the OVA and OVA-RHO groups) or normal saline
(given to the SAL groups) delivered into the inspiratory
circuit through the air inlet of the ventilator. Measure-
ments of the Ptr and V’ were taken 1 and 3 min after the
beginning of the first OVA/SAL challenge. Respiratory
system elastance (Ers) and resistance (Rrs) were obtained
using the equation of motion of the respiratory system:
Ptr(t) = Ers · V(t) + Rrs · V’(t), where t represents time.
Immediately after the end of the mechanical evalu-
ation, a positive end-expiratory pressure of 5 cmH2O
was applied and the trachea was occluded with a 5.0
silk suture at the end of the expiration to maintain
lung inflation. Then, the guinea pigs were exsangui-
nated via the abdominal aorta, the anterior chest wall
was removed, and the lungs were removed en bloc.
The removed lungs were fixed with buffered 10 %
paraformaldehyde for 24 h and then transferred to
70 % ethanol to prepare histological slides for mor-
phometric analysis.
Lung oscillatory mechanics
After the last inhalation exposure (72 h), the animals were
anaesthetized with pentobarbital sodium (50 mg/kg) and a
tracheotomy was performed. Afterwards, the thorax was
opened and the animals were exsanguinated. The lungs
were removed en bloc and placed in a modified Krebs-
Henseleit (K-H) solution (containing, in mM: 118.4 NaCl,
4.7 KCl, 1.2 K3PO4, 25 NaHCO3, 2.5 CaCl2 · H2O,
0.6 MgSO4 · H2O, and 11.1 glucose) at pH = 7.40 and 6 °C
(63). Strips (2 × 2 × 10 mm) were cut from the periphery
of the left lung and suspended vertically in a K-H organ
bath that was maintained at 37 °C and continuously
bubbled with a mixture of 95 % O2-5 % CO2. The lung
strips were weighed, and their unloaded resting lengths
(L0) were determined using a caliper. The lung strip vol-
ume was measured by simple densitometry and calculated
as: volume =ΔF/δ, where ΔF is the total change in force
before and after immersion of the strip in K-H solution,
and δ is the mass density of K-H solution [34]. Parenchy-
mal strips were suspended vertically in a K-H organ bath
(30 mL internal volume) that was maintained at 37 °C and
continuously bubbled with 95 % O2-5 % CO2, as previ-
ously described [43]. Briefly, one end of the strip was at-
tached to a force transducer (LETICA TRI-110; Scientific
Instruments, Barcelona, Spain) and the other was fastened
to a lever arm actuated by means of a modified woofer,
driven by a computer-generated signal and digitally con-
verted (AT-MIO-16-E-10, National Instruments, Austin,
TX). A sidearm of this rod was linked to a second force
transducer (LETICA TRI-110; Scientific Instruments) by
means of a silver spring of a known Young's modulus,
thus allowing for the measurement of displacement. Nei-
ther amplitude dependence (<0.1 % change in stiffness)
nor phase changes with frequency were detected in the
0.01- to 14-Hz range. The hysteresivity of the system
(<0.003) was frequency-independent.
A cross-sectional, unstressed area (A0) of the strip was
identified from the volume and the unstressed length as
calculated according to A0 = vol/L0. The basal force (FB)
for a stress of 0.1 N/cm2 was calculated as FB (N) = 10
(N/cm2) × A0 (cm
2) and adjusted by vertical displace-
ment of the force transducer, as previously described
[25]. The displacement signal was then set to zero. Once
the basal force and displacement signals were adjusted,
the length between bindings (LB) was measured using a
precision caliper. The instantaneous length during oscil-
lation around LB was determined by adding the value of
LB to the measured value of displacement at any given
time. The instantaneous average cross-section area (Ai)
was determined as Ai = vol/Li (cm
2), where Li is the in-
stantaneous length.
The instantaneous stress (σi) was calculated by dividing
force (F; in g) by Ai (cm2) using the equation σi = F/Ai. The
strain was calculated as Δε = (L – LB)/LB. After the basal
force was adjusted to 0.5 × 10−2 N, each parenchymal strip
was preconditioned by sinusoidal oscillation of the tissue
for 30 min (frequency = 1 Hz, which is a large enough
amplitude to reach a final force of 1 × 10−2 N). Thereafter,
the amplitude was adjusted to 5 % L0, and the oscillation
was maintained for another 30 min, or until a stable
length-force loop was reached. The isometric stress adapta-
tion period resulted in a final force of 0.5 × 10−2 N. After
preconditioning, the strips were oscillated at a fre-
quency (f ) of 1 Hz [42] and with a constant force of
0.5 × 10−2 N. The bath solution was renewed every
20 min with 37 °C K-H solution.
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All mechanical parameters were measured cycle by
cycle. The tissue resistance (Rt) was determined from the
enclosed area of force length loops: R = (4 × H)/[π × ω ×
(Δε)2], where H is the stress–strain hysteresis area, ω is
the angular frequency [ω = 2πf (rad/s), where f is the fre-
quency], and Δε is the normalized strain or peak-to-peak
change in the length divided by LB. The tissue dynamic E
was determined as: Et = (Δσι/Δε)cosθ, where Δσι is the
peak-to-peak change in force, and θ is the phase lag be-
tween force and displacement [(θ = sin−1{4 × H/[π(Δσι ×
Δε)})]. The η, which is an empirically determined variable
that quantifies the dependence of dissipative processes on
elastic processes, was calculated as η = tan θ. The tissue
resistance (Rt), elastance (Et), and hysteresivity (η) were
calculated for the baseline condition and after ovalbumin
challenge (dose of 0.1 % of ovalbumin) [8].
The lung strips were fixed with buffered 10 % parafor-
maldehyde for 24 h and then transferred to 70 % ethanol
to prepare histological slides for morphometric analysis.
Morphometric analysis
The homogeneity of the strip samples was assured by
measuring the fractional area of the tissue constituents
using the point-counting method [1, 34, 53] and a 100-
point grid with a known area (62,500 μm2 at 400× magni-
fication) attached to the ocular of the microscope. We
measured the fractional area of the bronchial wall (BW),
the blood vessel wall (BVW), and the alveolar wall (AW)
as the number of points that fell within BW, BVW or AW
divided by the total number of points that fell within the
strip tissue. The measurements were performed in 10
fields per slide at 400× magnification. We calculated the
mean values for each animal.
All morphometric evaluations were performed by a
blind analysis. The histologic slides were not named with
the names of the groups and the researcher had no know-
ledge of the procedures for each group.
Evaluation of eosinophils
Lung strips that were 5 μm thick were stained with LUNA
for eosinophil evaluation [1, 41, 49]. The percentage of
eosinophils in the lung parenchyma and the airway was
evaluated through morphometric analysis using a reticule
of known area (50 lines and 100 dots) and a microscope
(CH30, Olympus, Japan). Positive cells were quantified at
a magnification of 1000× using the ratio of points identify-
ing such cells in a known area to the total number of
points within the lung tissue and airway. The results are
expressed in cells per unit area (104 μm2). The quantifica-
tion was performed in 10 random fields in the distal lung
and three fields of the airway wall, from 3–5 airways per
animal. Several authors have previously demonstrated that
this method is adequate and reproducible [25, 36].
Picro-Sirius and Resorcin-Fuchsin staining
Picro-Sirius staining was used to quantify collagen fibers
and Resorcin-Fuchsin staining was used to identify elastic
fibers in the airways and lung tissue. The volume fraction
of collagen and elastic fibers in the airways and the alveo-
lar tissue of the lung strips was determined (10 fields and
3–5 airways, 400×) by dividing the number of points con-
tained within collagen or elastic fibers by the total number
of points within the airway and lung tissue. The results
are expressed as percentages [37, 38].
Immunohistochemical evaluation
Immunohistochemical evaluation was performed using
the following dilutions of primary antibodies: 1:400
(IL-2 – cod. sc- 7896), 1:500 (IL-4 – cod. sc-1260),
1:200 (IL-5 – cod. sc-7887), 1:200 (IL-13 – cod. 1776),
1:150 (IFN-γ – cod. sc-8308), 1:150 (NF-κB – cod. sc-109),
1:250 (MMP-9 – cod. sc-6840), 1:250 (TIMP-1 – cod.
sc-5538), 1:1500 (TGF-β – cod. sc-146), all from Santa
Cruz Biotechnology, Santa Cruz, CA. The anti-8-iso-pros-
taglandin F (PGF) 2α antibody (Oxford Biomedical
Research, Rochester Hills, MI – cod. IS20) was used
at a 1:500 dilution and the anti-iNOS antibody (BD
Transduction Laboratories, San Diego, CA, USA, cod.
N32020) was used at a 1:250 dilution. The following se-
quence of procedures was used to stain the samples:
antigenic recovery, blockage and incubation with pri-
mary antibody, incubation with secondary antibody
complex, staining and counterstaining. The slides were
prepared and counts were performed in 10 random
fields per sample, as described above for the evaluation
of eosinophils.
Passive cutaneous anaphylaxis reaction
To evaluate whether Rho-kinase inhibitor and/or cortico-
steroid treatment interfered with sensitization to ovalbu-
min, we measured the production of IgE and IgG1
antibodies to ovalbumin by passive cutaneous anaphylaxis
(PCA), as previously described [32]. Three guinea pigs
from each experimental group were anesthetized with
pentobarbital sodium (50 mg/kg i.p.) on day 26 and 5 mL
of blood were collected by cardiac puncture. Antibody
titers were estimated by determining the highest dilution
of antiserum that induced a PCA reaction. It is important
to clarify that this procedure was performed one week
after the seventh inhalation.
Statistical analysis
All statistical analyses were performed using the
SigmaStat software (SPSS Inc., USA). All data represent
the means ± standard error (S.E.). The statistical signifi-
cance of the differences between groups was determined
using a One-Way Analysis Of Variance (ANOVA) followed
by the Holm-Sidak method for multiple comparisons. We
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also obtained the Pearson correlation coefficient (R) to as-
sess the associations of the pulmonary mechanical scores
with the markers for inflammation, remodeling and oxida-
tive stress. Differences were considered significant when
P < 0.05.
Results
Inhalation time
There were no differences in the inhalation time among
the groups studied until the fourth inhalation, and all of
the animals reached 900 s of inhalation (Fig. 2). None of
the animals in the normal saline group presented with
respiratory distress during the seven inhalation expo-
sures. From the fifth to the seventh inhalation, sensitized
and non-treated animals (OVA group) presented lower
inhalation times compared to the groups sensitized and
treated with Y-27632, the corticosteroid or Y-27632 and
the corticosteroid (OVA-RHO, OVA-C and ORC groups,
respectively; P < 0.05). There was a significant difference
between the OVA-RHO and OVA-C groups (P < 0.05).
Exhaled nitric oxide
The concentrations of ENO were higher in the OVA
group than in the SAL group (P < 0.001). However, treat-
ment with Y-27632, the corticosteroid or Y-27632 and
the corticosteroid reduced the level of ENO compared
with the OVA group (P < 0.05). There were no signifi-
cance differences among the OVA-RHO, OVA-C and
ORC groups (Fig. 3).
Mechanical evaluation
Measurements of respiratory system mechanics
Compared to the baseline values of Rrs and Ers, there
were no differences among the groups (data not shown).
The percentage of the maximal increase in airway Rrs is
shown in Fig. 4a. There was a significant increase in the
%Rrs of the OVA group compared to the control (SAL
group, P < 0.001). The treatment of sensitized animals
with the Rho-kinase inhibitor, the corticosteroid or both
the Rho-kinase inhibitor and the corticosteroid attenuated
this response (OVA-RHO, OVA-C and ORC groups, re-
spectively) compared with the OVA group (P < 0.001).
The percentage of the maximal increase in airway Ers
is shown in Fig. 4b. There was a significant increase in
the %Ers of the OVA group compared to the control
(SAL group, P < 0.001). The treatment of the sensitized
animals with the Rho-kinase inhibitor, the corticosteroid
or both the Rho-kinase inhibitor and the corticosteroid
(OVA-RHO, OVA-C and ORC groups, respectively) at-
tenuated this response compared with the OVA group
(P < 0.001). There was no potentiation of this response
in the ORC group.
Measurements of lung tissue oscillatory mechanics
Compared to the baseline values of Rt and Et, there were
no differences among the groups (data not shown). The
percentage of the maximal increase in airway Rt is
shown in Fig. 4c. There was a significant increase in the
%Rt of the OVA group compared to the control (SAL
group, P < 0.001). The treatment of the sensitized ani-
mals with the Rho-kinase inhibitor, the corticosteroid or
both the Rho-kinase inhibitor and the corticosteroid
(OVA-RHO, OVA-C and ORC groups, respectively) at-
tenuated this response compared with the OVA group
(P < 0.05).
The percentage of the maximal increase in airway %Et
is shown in Fig. 4d. There was a significant increase in
the %Et of the OVA group compared to the control
(SAL group, P < 0.001). The treatment of sensitized ani-
mals with the Rho-kinase inhibitor, the corticosteroid or
Fig. 2 Vertical bar graph showing the mean ± SEM of the inhalation
time. *P < 0.05, compared with the OVA-RHO, OVA-C and ORC
groups. **P < 0.001, compared with the SAL group. #P < 0.05,
compared with the OVA-C group
Fig. 3 Vertical bar graph representing the mean ± SEM of the ENO
concentrations of the anesthetized guinea pigs. The ENO was
collected 72 h after the 7th exposure (before the challenge) to
saline or OVA solutions in the 5 experimental groups. *P < 0.05,
compared with the OVA-RHO, OVA-C and ORC groups. **P < 0.05,
compared with the SAL group
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both the Rho-kinase inhibitor and the corticosteroid
(OVA-RHO, OVA-C and ORC groups, respectively) at-
tenuated this response compared with the OVA group
(P < 0.05).
There were no differences in the maximal responses
in %Et and %Rt among the OVA-RHO, OVA-C and ORC
groups.
Morphometric analysis
All of the groups showed a similar anatomical compos-
ition of the lung strips, with approximately 90 % of the
strip being the alveolar wall (SAL group: 93.2 ±
1.10 %, OVA group: 92.3 ± 0.76 %, OVA-RHO group:
92.6 ± 1.29 %, OVA-C group: 93.4 ± 0.85 and ORC
group: 98.0 ± 0.68 %).
Effects on inflammation
The absolute values for the number of eosinophils and
the cellular inflammation markers, IFN-γ, IL-2, IL-4,
IL-5 and IL-13, present in the four experimental groups
are shown in Table 1 (airway and lung tissue).
In the airways and lung tissue, there was an increase
in the eosinophil density in the OVA group compared
with the SAL group (P < 0.001). The OVA-RHO, OVA-C
and ORC groups had a reduced eosinophil density in the
airways and lung tissue compared with the OVA group
(P < 0.05). In the lung tissue of the OVA-RHO and ORC
groups, there was a reduction in the eosinophil density
compared with the OVA-C group, (P < 0.05).
We observed an increase in IFN-γ-positive cells in the
airways and lung tissue in the OVA group compared
with the SAL group (P < 0.001). The OVA-RHO, OVA-C
and ORC groups had a reduced number of IFN-γ-
positive cells in the airways and lung tissue compared
with the OVA group (P < 0.001). There was a reduction
in the number of IFN-γ-positive cells in the airways and
lung tissue of the ORC group compared with the OVA-
RHO and OVA-C groups (P < 0.05).
There was an increase in the number of IL-2-positive
cells in the airways and lung tissue from the OVA group
compared with the SAL group (P < 0.001). The OVA-
RHO, OVA-C and ORC groups had a reduced numbers
of IL-2-positive cells in the airways and lung tissue com-
pared with the OVA group (P < 0.001). Notably, there
was also a significant decrease in the number of IL-2-
positive cells in the lung tissue from the ORC group
compared to tissue from the OVA-RHO and OVA-C
groups (P < 0.05).
There was an increase in the number of IL-4-positive
cells in the airways and lung tissue from the OVA group
compared with the SAL group (P < 0.001). The OVA-
RHO, OVA-C and ORC groups had reduced numbers of
IL-4-positive cells in the airways and lung tissue com-
pared with the OVA group (P < 0.001).
Fig. 4 The vertical bars graph shows the mean ± SEM of the maximal percent increase in respiratory system resistance (Rrs) (a), respiratory system
elastance (Ers) (b), lung tissue resistance (Rt) (c) and lung tissue elastance (Et) (d) obtained after airway and lung tissue challenge with ovalbumin
or normal saline in anaesthetized guinea pigs. *P < 0.001, compared with the OVA-RHO, OVA-C and ORC groups. **P < 0.05, compared with the
SAL group
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There was an increase in the numbers of IL-5- and IL-
13-positive cells in the airways and lung tissue from the
OVA group compared with the SAL group (P < 0.001).
The OVA-RHO, OVA-C and ORC groups had re-
duced numbers of IL-5- and IL-13-positive cells in
the airways and lung tissue compared with the OVA
group (P < 0.05).
Figure 5 presents photomicrographs of the airway
walls from guinea pigs in the experimental groups sub-
jected to LUNA staining for the detection of eosinophil
density and immunohistochemical staining for IFN-γ,
IL-2, IL-4, IL-5 and IL-13 detection.
Effects on extracellular matrix remodeling
The absolute values of the remodeling markers for the
volume fraction of collagen, elastic fibers and actin,
TGF-β, MMP-9 and TIMP-1-positive cells in the four
experimental groups are shown in Table 2 (airway and
lung tissue).
We observed an increase in the volume fraction of colla-
gen fibers in the airways and lung tissue from the OVA
group compared to the SAL group (P < 0.001). The OVA-
RHO, OVA-C and ORC groups showed a reduction in the
volume fraction of collagen fibers in the airways and lung
tissue compared to the OVA group (P < 0.05). There was
also a reduction of the volume fraction of collagen fibers
in the airways of the ORC group compared to the OVA-
RHO and OVA-C groups (P < 0.05).
There was an increase in the volume fraction of elastic
fibers and actin in the airways and lung tissue from the
OVA group compared with the SAL group (P < 0.001).
The OVA-RHO, OVA-C and ORC groups had a reduced
volume fraction of elastic fibers and actin in the airways
and lung tissue compared with the OVA group (P < 0.05).
There were no differences among the OVA-RHO, OVA-C
and ORC groups (P < 0.05).
There was an increase in the number of TGF-β-positive
cells in the airways and lung tissue from the OVA group
compared with the SAL group (P < 0.001). The OVA-
RHO, OVA-C and ORC groups had reduced numbers of
TGF-β-positive cells in the airways and lung tissue com-
pared with the OVA group (P < 0.05).
The number of MMP-9-positive cells is shown in
Table 2. There was an increase in the number of MMP-9-
positive cells in the airways and lung tissue from the OVA
group compared with the SAL group (P < 0.001). The
OVA-RHO, OVA-C and ORC groups had reduced num-
bers of MMP-9-positive cells in the airways and lung tis-
sue compared with the OVA group (P < 0.001).
There was an increase in the number of TIMP-1-
positive cells in the airways and lung tissue from the OVA
group compared with the SAL group (P < 0.05). The
OVA-RHO, OVA-C and ORC groups had reduced num-
bers of TIMP-1-positive cells in the airways and lung tis-
sue compared with the OVA group (P < 0.05). There was a
reduction in the number of TIMP-1 positive cells in the
ORC group compared to the OVA-RHO and OVA-C
groups, but only in the lung tissue (P < 0.05).
Representative photomicrographs of the airways of the
animals stained with Picrosirius for collagen content,
Table 1 Absolute values of the morphometric analysis for inflammatory markers in the airway and lung tissue
AIRWAY
BIOMARKERS SAL (n = 8) OVA (n = 8) OVA-RHO (n = 8) OVA-C (n = 8) ORC (n = 8)
Eosinophils 4.15 ± 1.26 33.56 ± 4.66 *** 12.17 ± 1.57 */ # 16.83 ± 4.34 * 11.46 ± 3.74 *
IFN-γ 9.37 ± 0.97 35.36 ± 2.50 *** 17.98 ± 1.14 + 18.02 ± 0.83 + 12.48 ± 1.44 + / **
IL-2 2.39 ± 0.57 32.76 ± 6.95 *** 13.31 ± 0.62 + 12.47 ± 0.97 + 10.09 ± 1.29 +
IL-4 4.69 ± 0.68 13.69 ± 1.26 *** 6.34 ± 1.58 + 8.13 ± 1.24 + 5.61 ± 0.85 +
IL-5 4.53 ± 0.75 21.76 ± 1.23 *** 11.43 ± 1.74 * 11.65 ± 2.12 * 9.67 ± 1.34 *
IL-13 1.19 ± 0.75 13.42 ± 0.45 *** 4.37 ± 1.12 * 6.64 ± 1.58 * 4.59 ± 0.68 *
LUNG TISSUE
BIOMARKERS SAL (n = 8) OVA (n = 8) OVA-RHO (n = 8) OVA-C (n = 8) ORC (n = 8)
Eosinophils 0.75 ± 0.27 11.48 ± 0.75 *** 4.13 ± 0.15 */ # 6.15 ± 2.19 * 2.73 ± 1.22 */ #
IFN-γ 11.26 ± 1.47 25.48 ± 1.13 *** 16.27 ± 0.76 + 19.08 ± 0.61 + 13.81 ± 0.78 + / **
IL-2 2.79 ± 0.49 19.53 ± 1.39 *** 7.48 ± 0.62 + 9.26 ± 0.45 + 4.13 ± 0.60 + / **
IL-4 2.57 ± 0.37 18.78 ± 1.53 *** 11.26 ± 0.92 + 8.32 ± 0.40 + 6.89 ± 0.96 +
IL-5 2.25 ± 0.54 13.52 ± 0.66 *** 5.76 ± 0.47 * 7.04 ± 0.93 * 5.90 ± 1.00 *
IL-13 1.38 ± 0.59 11.37 ± 2.26 *** 4.74 ± 1.32 * 3.61 ± 1.07 * 2.62 ± 0.76 *
The eosinophils, IFN-γ, IL-2, IL-4, IL-5, IL-13, are expressed in positive cells/104 μm2. ***P < 0.001, compared with the SAL group; *P < 0.05, compared with the OVA
group; #P < 0.05, compared with the OVA-C group, +P < 0.001, compared with the OVA group, **P < 0.05, compared with the OVA-RHO and OVA-C groups
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Weighert Resorcin-Fuchsin for elastic fiber content, and
immunohistochemical staining for actin, TGF-β, MMP-9,
TIMP-1 detection are shown in Fig. 6.
Effects on oxidative stress and NF-ĸB expression
The absolute values of the oxidative stress and nuclear
factor markers, including the number of iNOS-positive
cells, the volume fraction of 8-iso-PGF2α and the number
of NF-κB-positive cells in the four experimental groups,
are shown in Table 3 (airway and lung tissue).
The number of iNOS-positive cells in the airway
and lung tissue was significantly higher in the OVA
group compared with the SAL group (P < 0.001). The
OVA-RHO, OVA-C and ORC groups had reduced
numbers of iNOS-positive cells in the airways and
lung tissue compared with the OVA group (P < 0.05).
The volume fraction of 8-iso-PGF2α in the airway and
lung tissue was significantly higher in the OVA group
compared with the SAL group (P < 0.001). The OVA-
RHO, OVA-C and ORC groups had a reduction in the
volume fraction of 8-iso-PGF2α in the airways and lung
Fig. 5 Photomicrographs of the immunohistochemical analyses of the airway walls to detect eosinophils (A1-A5, X400); IFN-γ (B1-B5, X400), IL-2
(C1-C5, X400), IL-4 (D1-D5, X400), IL-5 (E1-E5, X400) and IL-13 (F1-F5, X400) in guinea pigs exposed to saline (a1, b1, c1, d1, e1 and f1) or ovalbumin
(a2, b2, c2, d2, e2 and f2). The treated guinea pigs exposed to Y-27632 (a3, b3, c3, d3, e3 and f3), to corticosteroid (a4, b4, c4, d4, e4 and f4) or to
Y-27632 combined with corticosteroid (a5, b5, c5, d5, e5 and f5) are also shown
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tissue compared with the OVA group (P < 0.05). There
was also a reduction in 8-iso-PGF2α in the ORC group
compared with the OVA-RHO and OVA-C groups, but
only in the lung tissue (P < 0.05).
The number of NF-κB-positive cells in the airway and
lung tissue was significantly higher in the OVA group
compared with the SAL group (P < 0.001). The OVA-
RHO, OVA-C and ORC groups had reduced numbers of
NF-κB-positive cells in the airways and lung tissue com-
pared with the OVA group (P < 0.05). There was also a re-
duction in NF-κB-positive cells in the ORC group
compared with the OVA-RHO and OVA-C groups, but
only in the lung tissue (P < 0.05).
Representative photomicrographs of the immunohisto-
chemical staining for iNOS, 8-iso-PGF2α and NF-κB in
the airways of the all experimental groups are shown in
Fig. 7.
Passive Cutaneous Anaphylaxis (PCA)
The specific antibody titration of IgG1 in the OVA ani-
mals was 1:640. However, the sensitized animals treated
with the corticosteroid, the Rho-kinase inhibitor or both
had lower levels of the specific IgG1 in the OVA-RHO
group (1:160), the OVA-C group (1:160) and the ORC
group (1:20). None of the groups had a PCA reaction to
the specific IgE at any dilution of antiserum.
Discussion
In the present study, we evaluated the effects of treatment
with the Rho-kinase inhibitor Y-27632, the corticosteroid
dexamethasone, or both, on guinea pigs with chronic
allergic inflammation. Our analysis focused on the
mechanical responses, inflammation, remodeling, and
production of oxidative stress in the airways and lung
parenchyma. The final results showed that both of the
individual treatments were effective in reducing the
maximum resistance and elastance of the respiratory
system and lung parenchyma when challenged with
antigen, suggesting that Rho-kinase inhibition or cor-
ticosteroid treatment modulate the constriction of the
airways and lung parenchyma. There was also a re-
duction in ENO, eosinophilic infiltration, Th1/Th2 in-
flammatory cytokines, extracellular matrix remodeling,
actin content, the number of NF-ĸB-positive cells and
oxidative stress.
The combination of the Rho-kinase inhibitor with the
corticosteroid decreased all of the functional and histo-
logical parameters to the same extent as the individual
treatments, in addition to maximizing the reduction of
collagen and IFN-γ in the airways, the number of cells
positive for IL-2, IFN-γ, NF-ĸB and the volume fraction
of 8-iso-PGF2α in the distal lung tissue.
In the lung parenchyma, the combined treatment of Y-
27632 with the corticosteroid maximized the reduction in
the eosinophil counts and TIMP-1-positive cells when
compared to animals treated only with the corticosteroid.
Notably, no previous studies have examined repeated
treatment with a Rho-kinase inhibitor combined with a
corticosteroid as a therapeutic strategy for the control of
hyperresponsiveness, remodeling and inflammatory al-
terations induced by chronic allergic inflammation in
the airways and distal lung tissue.
Table 2 Absolute values of the morphometric analysis for remodeling markers in the airway and lung tissue
AIRWAY
BIOMARKERS SAL (n = 8) OVA (n = 8) OVA-RHO (n = 8) OVA-C (n = 8) ORC (n = 8)
Collagen Fibers 9.13 ± 0.36 25.54 ± 1.95 *** 15.95 ± 0.94 * 19.60 ± 1.89 * 10.31 ± 0.97 * / **
Elastic Fibers 2.26 ± 0.43 17.68 ± 2.47 *** 4.53 ± 0.59 * 9.33 ± 0.67 * 4.87 ± 0.52 *
Actin 6.94 ± 0.67 25.59 ± 2.26 *** 12.16 ± 1.25 * 19.97 ± 0.94 * 15.30 ± 1.23 *
TGF-β 4.48 ± 0.53 13.47 ± 1.74 *** 5.35 ± 1.78 * 7.73 ± 1.58 * 5.67 ± 0.91 *
MMP-9 12.35 ± 0.78 26.48 ± 1.48 *** 11.29 ± 1.38 + 13.36 ± 0.49 + 10.82 ± 1.34 +
TIMP-1 4.63 ± 1.25 17.17 ± 1.36 *** 8.13 ± 0.73 * 9.82 ± 1.27 * 7.30 ± 0.98 *
LUNG TISSUE
BIOMARKERS SAL (n = 8) OVA (n = 8) OVA-RHO (n = 8) OVA-C (n = 8) ORC (n = 8)
Collagen Fibers 8.62 ± 0.28 22.42 ± 0.68 *** 9.74 ± 0.64 * 13.76 ± 0.32 * 12.35 ± 1.73 *
Elastic Fibers 7.74 ± 0.69 19.49 ± 0.52 *** 12.93 ± 1.37 * 12.85 ± 0.51 * 8.05 ± 1.59 *
Actin 4.52 ± 0.98 13.24 ± 0.74 *** 4.65 ± 0.85 * 4.86 ± 0.84 * 4.94 ± 0.90 *
TGF-β 5.90 ± 0.63 15.24 ± 0.36 *** 6.37 ± 0.69 * 6.46 ± 1.13 * 5.69 ± 0.74 *
MMP-9 12.53 ± 0.95 27.17 ± 0.35 *** 14.53 ± 0.55 + 14.92 ± 0.81 + 13.55 ± 0.56 +
TIMP-1 3.95 ± 0.74 17.19 ± 1.12 *** 12.58 ± 0.59 * 12.18 ± 1.27 * 8.32 ± 1.12 * / **
The collagen fibers, elastic fibers and actin are expressed in percentage of increase (%).The TGF-β, MMP-9 and TIMP-1 are expressed in positive cells/104 μm2.
***P < 0.001, compared with the SAL group; *P < 0.05, compared with the OVA group; #P < 0.05, compared with the OVA-C group, +P < 0.001, compared with the
OVA group, **P < 0.05, compared with the OVA-RHO and OVA-C groups
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To avoid interfering with the animals’ sensitization, we
started treatment with the corticosteroid and/or Y-27632
twenty-four hours after the fourth ovalbumin inhalation
exposure. Using the PCA technique, we found that the
sensitized animals had an increase in specific IgG1 ana-
phylactic antibodies.
The inhalation time was recorded to evaluate the
acute responses to antigen exposure, as previously
described [51]. Treatment with the Rho-kinase in-
hibitor, the corticosteroid or the combination of
these therapies attenuated the acute response in
sensitized animals. The use of Y-27632 alone in-
creased the contact time with the antigen when
compared to the corticosteroid-treated group in sen-
sitized animals. This most likely occurred because of
the muscle-relaxing action of the Rho-kinase inhibitor
(Y-27632) on the airway smooth muscle [46] and on
the myocontractile elements of the lung parenchyma,
resulting in diminished signs of respiratory distress
and increased inhalation time. On the other hand,
dexamethasone affects mainly the inflammatory com-
ponent of asthma.
Fig. 6 Representative photomicrographs of guinea pig airways stained with Picrosirius for collagen content (A1-A5, X400), Weighert Resorcin-
Fucsin for elastic fiber content (B1-B5, X400), actin (C1-C5, X400), TGF-β (D1-D5, X400), MMP-9 (E1-E5, X400) and TIMP-1 (F1-F5, X400) in guinea
pigs exposed to saline (a1, b1, c1, d1, e1 and f1) or ovalbumin (a2, b2, c2, d2, e2 and f2). The treated guinea pigs exposed to Y-27632 (a3, b3,
c3, d3, e3 and f3), to corticosteroid (a4, b4, c4, d4, e4 and f4) Y-27632 combined with corticosteroid (a5, b5, c5, d5, e5 and f5) are also shown
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We believe that several mechanisms contributing to
the acute responses to antigen challenge, including
smooth muscle contraction, were most likely altered by
treatment with Y-27632 and the protective effect of the
corticosteroid [25, 36].
As a confirmation that these three treatments (separate
use of Y-27632 and the corticosteroid, and the combined
use of the corticosteroid with Y-27632) can effectively con-
trol the inflammatory process, we observed a significant
reduction in ENO among the animals sensitized with
ovalbumin.
The ENO level has been proposed as an indirect
marker of lung inflammation and correlates with the
severity and response to the treatments. It is also ele-
vated in asthmatics and animal models of chronic pul-
monary inflammation [2, 25, 36]. Nitric oxide is involved
in various mechanisms of asthma physiopathology. Pre-
vious studies have demonstrated that nitric oxide de-
rived from constitutive isoforms has protective effects
on bronchoconstriction and remodeling [37], whereas
nitric oxide produced by iNOS is involved in the con-
striction, inflammation and remodeling processes [38,
49].
The maximum elastance and resistance responses after
antigen challenge decreased in both the respiratory sys-
tem and the distal pulmonary tissue when the sensitized
Table 3 Absolute values of the morphometric analysis for oxidative stress and transcription factor markers in the airway and
lung tissue
AIRWAY
BIOMARKERS SAL (n = 8) OVA (n = 8) OVA-RHO (n = 8) OVA-C (n = 8) ORC (n = 8)
iNOS 5.46 ± 0.17 17.44 ± 1.47 *** 7.47 ± 0.85 * 10.20 ± 2.12 * 9.70 ± 0.81 *
8-iso-PGF2α 11.25 ± 0.38 26.47 ± 1.28 *** 14.48 ± 2.97 * 15.26 ± 1.37 * 13.28 ± 1.16 *
NF-κB 6.18 ± 0.48 17.36 ± 1.46 *** 7.69 ± 0.42 * 7.29 ± 1.34 * 5.35 ± 0.89 *
LUNG TISSUE
BIOMARKERS SAL (n = 8) OVA (n = 8) OVA-RHO (n = 8) OVA-C (n = 8) ORC (n = 8)
iNOS 1.26 ± 0.37 10.14 ± 0.38 *** 4.37 ± 0.85 * 5.42 ± 0.94 * 4.67 ± 0.37 *
8-iso-PGF2α 1.15 ± 0.38 18.84 ± 1.85 *** 9.48 ± 0.85 * 10.14 ± 0.73 * 2.18 ± 0.54 * / **
NF-κB 1.38 ± 0.31 18.37 ± 1.78 *** 11.37 ± 1.63 * 10.88 ± 0.96 * 5.70 ± 0.94 * / **
The iNOS and NF-κB are expressed in positive cells/104 μm2. The 8-iso-PGF2α is expressed in percentage of increase (%). ***P < 0.001, compared with the SAL
group; *P < 0.05, compared with the OVA group; **P < 0.05, compared with the OVA-RHO and OVA-C groups
Fig. 7 Representative photomicrographs of guinea pig airways stained with immunohistochemistry results for iNOS (A1-A5, X400), 8-iso-PGF2α
(B1-B5, X400) and NF-κB (C1-C5, X400) in guinea pigs exposed to saline (a1, b1 and c1) or ovalbumin (a2, b2 and c2). The treated guinea pigs
exposed to Y-27632 (a3, b3 and c3), to corticosteroid (a4, b4 and c4) or to Y-27632 combined with corticosteroid (a5, b5 and c5) are also shown
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animals were treated with Y-27632, the corticosteroid, or a
combination of both treatments, compared to the animals
that received the vehicle. To further investigate the mech-
anisms involved in the control of the mechanical re-
sponses, we evaluated the volume fraction of actin in the
airways and in the lung parenchyma of sensitized and
treated guinea pigs. There was a decrease in the volume
fraction of actin in the airway walls and alveolar septa in
the treated groups compared to the untreated groups.
The results from different studies using the same model
of experimental asthma have shown that treatment with
Y-27632 is effective in decreasing the actin content in the
airways [36] and in the distal parenchyma [41], but none
of the studies assessed the effects of this inhibitor com-
bined with corticosteroids. In the current study, the
Rho-kinase inhibitor, alone or in combination with a
corticosteroid, was able to reduce the volume fraction of
actin compared to the OVA group.
There is evidence that activated Rho-kinase regulates
actin/myosin contractibility regardless of the level of free
calcium [31]. Actin is part of the cytoskeleton of endo-
thelial cells, and the presence of inflammatory agonists
increases cytosolic calcium levels. Increased calcium
levels diminish cAMP and activate RhoA/Rho-kinase,
causing the reorganization of the cortical actin into
stress fibers, which are bundles of actin/myosin neces-
sary to induce cell contraction [39]. In the distal paren-
chyma, the actin is localized in the myocontractile
elements, such as myofibroblasts.
Corticosteroids may directly or indirectly modulate the
contraction of the airway smooth muscle by suppressing
the agonistic responses induced by an increase in intracel-
lular calcium or by down-regulation linked to uncoupling
receptors (M2 or M3 muscarinic, H1 histaminic receptors).
In addition, corticosteroids can enhance the relaxation of
the airway smooth muscle by activating AMP cycle-
dependent or -independent mechanisms. The effects of
dexamethasone on human airway smooth muscle were
studied by Goldsmith et al. [10]. These authors showed
that in human bronchial cells, corticosteroids reduced the
level of smooth muscle-α and that such effects were medi-
ated, at least in part, by the attenuation of mRNA transla-
tion and increased protein degradation.
The combined treatments resulted in a reduction in the
number of cells positive for IFN-γ in the airways and in
the lung parenchyma. We also observed a greater reduc-
tion in eosinophils and IL-2 in the lung parenchyma when
both treatments were combined. Additionally, our results
showed that in the lung parenchyma, treatment with the
Rho-kinase inhibitor had a greater impact on reducing the
eosinophil counts than treatment with the corticosteroid,
showing that use of this drug by itself is promising.
In a related study, Souza et al. [48] investigated the
effects of the corticosteroid montelukast and 1400 W
(a selective iNOS inhibitor) in the peripheral lung tissue
of guinea pigs with chronic allergic pulmonary inflam-
mation. The results showed that the isolated use of
dexamethasone was able to reduce the eosinophilic infil-
trates and the number of Th1 (IFN-γ) and Th2 (IL-4
and IL-5) cells. Hence, the combination of an iNOS in-
hibitor and montelukast caused a maximized reduction
in IL-4, IL-5, and IFN-γ. In mice chronically exposed to
ovalbumin, chronic administration of budesonide re-
duced airway hyperresponsiveness, as well as leukocyte
infiltration, with a decrease in the production of Th2
mediators such as IL-4, IL-12, and eotaxin-1 [28].
The results of the present study corroborated data in
the literature describing the effect of a Rho-kinase in-
hibitor on eosinophil recruitment. Taki et al. [50] ob-
served that the Rho-kinase inhibitor Fasudil reduced the
number of eosinophils after allergen challenge, although
it did not affect the recruitment of other inflammatory
cells. Hashimoto et al. [14] demonstrated that the Rho-
kinase inhibitor Y-27632 had a key role in reducing the
infiltration and activation of inflammatory cells.
When we evaluated the alterations of the extracellular
matrix, particularly the volume fraction of collagen and
elastic fibers and the numbers of TIMP-1, MMP-9 and
TGF-ß positive cells, we observed a reduction in the air-
way and distal lung parenchyma of the sensitized ani-
mals treated with the Rho-kinase inhibitor or with the
corticosteroid. The combination of the corticosteroid
with Y-27632 enhanced the reduction in the volume
fraction of collagen fibers present in the airways. We
also observed a greater attenuation of TIMP-1-positive
cells in the lung parenchyma when both drugs were
combined.
These results can be explained, at least in part, by the
reduction in eosinophil recruitment and Th1/Th2 in-
flammatory cytokine levels, as demonstrated by the cor-
relation data.
Studies suggest the importance of Rho-kinase modula-
tion in the remodeling process. Zhou et al. [54] showed
that Rho-kinase activation is crucial to collagen synthe-
sis, which may be related to a combination of factors in-
cluding the inhibition of the c-Jun N-terminal kinase
(JNK) and TGF-ß pathways. Additionally, Kondrikov
et al. [22] concluded that oxygen toxicity induces ROS
to separate the guanine nucleotide dissociation inhibitor
(GDI, a regulator of Rho GTPase activity) from Rho-
kinase, leading to the activation of the Rho-kinase path-
way and contributing to an increase in type I collagen
synthesis.
Other studies suggest that inhaled corticosteroids are
unable to reduce the pulmonary remodeling responses
completely [16, 48]. In this regard, Goleva et al. [11]
showed that in asthmatics resistant to steroid treatment,
there was an MMP-9/TIMP-1 imbalance that promoted
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proteolysis and contributed to the chronic remodeling of
the airways and the non-reversibility of the bronchial
smooth muscle contraction.
Chakir et al. [3] studied bronchial biopsies of patients
with moderate and severe asthma treated with oral corti-
costeroids for two weeks. They showed that this treat-
ment was unable to reduce type I and II collagen or
TGF-ß. In contrast, the administration of beclometha-
sone in daily doses of 800 mg diminished the deposition
of collagen in patients with asthma [16]. Miller et al.
[30] demonstrated that corticosteroids inhibit TGF beta1
expression in eosinophils and macrophages. McMillan
et al. [28] demonstrated in mice chronically exposed to
ovalbumin that budesonide was able to reduce collagen
deposition and mucus production by regulating inflam-
mation and TGF beta1 signaling rather than by decreas-
ing TGF beta protein production.
Our evaluation of the importance of oxidative stress also
demonstrated an attenuation of the number of iNOS-
positive cells and the volume fraction of 8-iso-PGF2α in
sensitized animals treated solely with the Rho-kinase in-
hibitor Y-27632 or with the corticosteroid. When the
treatments were combined, all of these parameters dimin-
ished, but there was a greater reduction in 8-iso-PGF2α in
the distal pulmonary tissue.
It has been clearly demonstrated that iNOS activation
contributes to the promotion of peroxynitrite produc-
tion, which leads to lipid peroxidation and isoprostane
(8-iso-PGF2α) generation [31]. The isoprostanes contrib-
ute to smooth muscle contraction by acting through the
tyrosine kinases and Rho/Rho-kinase, leading to the de-
creased activity of myosin light-chain phosphatase and
increasing the level of phosphorylated myosin light-
chain and contraction [19].
McGown et al. [27] demonstrated that Fasudil reduced
LPS-induced iNOS superregulation, reducing microvascu-
lar inflammation. Jiang and George [20] demonstrated
that Rho-kinase inhibition with Y-27632 prevented the re-
duction of NO induced by TGF-β2, thus avoiding iNOS
inhibition, and suggesting that TGF-β2 inhibits iNOS
expression via a Rho-kinase-dependent pathway in pul-
monary epithelial cells.
We observed that the cellular expression of NF-κB was
reduced in animals treated with the Rho-kinase inhibitor
or with the corticosteroid in sensitized animals. The com-
bination of these treatments allowed for a maximized re-
duction of NF-κB in the distal pulmonary tissue.
The reduction of NF-κB-induced transcription might
result in an inhibition of RhoA upregulation induced by
IL-13 and TNF-α. Meyer-Schwesinger et al. [30] ob-
served that Rho-kinase inhibition attenuated NF-κB ex-
pression, resulting in protection against injury. These
data suggest that NF-κB expression may also be Rho-
kinase-dependent.
Conclusions
The data suggest that Rho-kinase inhibition or treatment
with corticosteroids can control the pulmonary mechan-
ical response, Th1 and Th2 lymphocyte and eosinophil
responses, extracellular matrix remodeling, and the pro-
duction of oxidative stress in the airways and distal par-
enchyma in this animal model. Combined treatment
with the Rho-kinase inhibitor and the corticosteroid
maximized the control of the remodeling response and
inflammation in the airways and parenchyma. Rho-
kinase inhibition alone or in combination with cortico-
steroids can be considered a future pharmacological tool
for the treatment of chronic pulmonary diseases.
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Rt: Lung tissue resistance; SAL: Animals that received normal saline;
TGF-β: Transforming growth factor beta; Th: T helper; TIMP-1: Tissue
inhibitor of metalloproteinases-1; Y-27632: (a pyridine derivative,
(+)-(R)-trans–4-(1-aminoethyl)-N-(4-pyridyl) cyclohexane carboxamide);
8-iso-PGF2α: 8-iso-prostaglandin F2alpha.
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